Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-30

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hospital acquired chest Infections are common complications in hospitalized cirrhotic patients. Infectious complications are the most common cause of mortality in cirrhotic patients with bronchopneumonia early antibiotic treatment at the base of culture and sensitivity is an optimal therapeutic approach in cirrhotics with nosocomial pneumonia Intensive care unit acquired pneumonia is the leading infection in critically ill patients and a major cause of morbidity and mortality despite recent major advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia

NCT01042353

Ventilator Acquired Pneumonia

COMPLETED PHASE4

Microbiological Profile of VAP Patients in Respiratory ICU

NCT05738928

VAP - Ventilator Associated Pneumonia

UNKNOWN

Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU

NCT04368221

Covid-19

COMPLETED

Staging Candidiasis in ICU Patients

NCT01322698

Candidiasis

COMPLETED

How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?

NCT04348227

Ventilator Associated Pneumonia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of the work

1. To estimate the frequency and risk factors of nosocomial chest infections in cirrhotic patients .
2. To determine the causative pathogens of nosocomial chest infections in patients with cirrhosis including fungal infections in order to establish our local empirical antimicrobial protocol.
3. To define the impact of nosocomial chest infections on survival of our patients.
4. To develop an effective and continuous surveillance program and infection control measures to reduce the burden of these infections as well as morbidity , mortality , hospital stay ,hospital cost and to achieve quality of care .
5. To motivate pharmaceutical companies to create a new umbrella coverage of antimicrobials through the ongoing knowledge of the changes in microbial resistance pattern inside hospitals

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nosocomial Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nosocomial infected cirrhotic patients

Diagnosis of bacterial infections

Intervention Type DIAGNOSTIC_TEST

Cultures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnosis of bacterial infections

Cultures

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All cirrhotic patients , decompensated , child pug score B or C ,may have Hepatocellular carcinoma , other comorbidities may present as (Diabetius mellitus , Hypertension , Heart disease and renal impairment ) , both sex and with clinical suspicion of chest infections acquired after 48 hours of admission

Exclusion Criteria

* Patients have any chronic chest disease
* Patients have severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and HIV-related disorders.

Eligible Sex

ALL

Accepts Healthy Volunteers

No